Covalent targeted radioligands potentiate radionuclide therapy

Xi‐Yang Cui, Zhu Li, Ziren Kong, +14

Nature

EngineeringMedicineRadionuclide TherapyTheranosticsRadiopharmaceuticals +5

18F-FDG-PET-based radiomics features to distinguish primary central nervous system lymphoma from glioblastoma

Ziren Kong, Chendan Jiang, Ruizhe Zhu, +9

NeuroImage Clinical

A Non-invasive Radiomic Method Using 18F-FDG PET Predicts Isocitrate Dehydrogenase Genotype and Prognosis in Patients With Glioma

Longfei Li, Wei Mu, Yaning Wang, +11

Frontiers in Oncology

Fusion Radiomics Features from Conventional MRI Predict MGMT Promoter Methylation Status in Lower Grade Gliomas

Chendan Jiang, Ziren Kong, Sirui Liu, +12

European Journal of Radiology

Neuro-oncologyFusion Radiomics FeaturesEngineeringMedical ImagingDiagnostic Neuroradiology +12

18F-FDG-PET-based Radiomics signature predicts MGMT promoter methylation status in primary diffuse glioma

Ziren Kong, Yusong Lin, Chendan Jiang, +11

Cancer Imaging

Conventional magnetic resonance imaging–based radiomic signature predicts telomerase reverse transcriptase promoter mutation status in grade II and III gliomas

Chendan Jiang, Ziren Kong, Yiwei Zhang, +12

Neuroradiology

Neuro-oncologyEngineeringGliomaMedicineGenetics +10

18F-Boramino acid PET/CT in healthy volunteers and glioma patients

Li Zhu, Ziren Kong, Junyi Chen, +5

European Journal of Nuclear Medicine and Molecular Imaging

Positron Emission TomographyNeuro-oncologyOncologic ImagingMedicinePet-mri +9

Radiomics signature based on FDG-PET predicts proliferative activity in primary glioma

Ziren Kong, Jiatong Li, Zehua Liu, +8

Clinical Radiology

Positron Emission TomographyNeuro-oncologyRadiomics SignatureMedicinePet-mri +10

Systematic identification, development, and validation of prognostic biomarkers involving the tumor‐immune microenvironment for glioblastoma

Binghao Zhao, Yuekun Wang, Yaning Wang, +6

Journal of Cellular Physiology

ImmunologyBiological MicroenvironmentsPathologyHigh-grade GliomasGlioma +19

86Y-Labeled Albumin-Binding Fibroblast Activation Protein Inhibitor for Late-Time-Point Cancer Diagnosis

Jie Ding, Mengxin Xu, Junyi Chen, +4

Molecular Pharmaceutics